Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Determining the prognostic significance of upfront radiation therapy in MM

Peter Barth • 14 Sep 2019
IMW 2019
Multiple Myeloma

Peter Barth, MD, of Brown University, Providence, RI, explains the rationale behind his research into the prognostic significance of upfront radiation therapy in multiple myeloma (MM). This was discussed at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Peter Barth

2:35
Bortezomib and lenalidomide as first-line treatment for older patients with myeloma
Peter Barth • 13 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals